Heym J, Koe B K
Department of Neuroscience, Pfizer Inc., Groton, CT 06340.
J Clin Psychiatry. 1988 Aug;49 Suppl:40-5.
Sertraline is a member of a new class of psychotherapeutic agents that selectively inhibit serotonin reuptake in the brain. Animal studies have demonstrated that inhibition of serotonin reuptake leads to enhanced serotonergic neurotransmission and indirectly results in a down-regulation of beta-adrenoceptors. The preclinical pharmacology of sertraline predicts antidepressant activity without accompanying anticholinergic, cardiotonic, or sedative side effects. Recent laboratory and clinical observations pertaining to body weight and obsessive compulsive disorder suggest the possibility of broader clinical indications for selective serotonin reuptake blockers such as sertraline.
舍曲林是一类新型心理治疗药物的成员,它能选择性抑制大脑中的5-羟色胺再摄取。动物研究表明,抑制5-羟色胺再摄取会导致5-羟色胺能神经传递增强,并间接导致β-肾上腺素能受体下调。舍曲林的临床前药理学表明其具有抗抑郁活性,且无伴随的抗胆碱能、强心或镇静副作用。最近有关体重和强迫症的实验室及临床观察表明,舍曲林等选择性5-羟色胺再摄取阻滞剂可能具有更广泛的临床适应症。